SYNEKTIK Baltic, a subsidiary of Synektik, has signed a contract to supply the first da Vinci robotic surgical system in Estonia. The robot will go to a hospital in Tallinn, and the contract also covers nine years of maintenance care and ten years of consumables supply. The total value of the agreement is EUR 9.4 million net, or around PLN 41 million. This makes Estonia the second Baltic state – after Lithuania – to receive a surgical robot from the Synektik Group.
The contract was awarded through a public tender, in line with Estonian public procurement law. In addition to the delivery, installation and commissioning of the da Vinci system and the training of hospital staff, the contract covers maintenance care during and after the warranty period — nine years in total — as well as a framework agreement for the successive supply of consumables over ten years. The equipment is to be delivered to the hospital within four months of the hospital notifying Synektik of the need for it.
Next step in the Baltic states, following Lithuania
This is the Synektik Group’s second contract for the supply of a da Vinci system in the Baltic states – following July’s agreement with Kaunas University Hospital in Lithuania – and its first in Estonia.
Synektik has been operating in Lithuania and Latvia since 2025, and in Estonia since 2026. As part of educational initiatives supporting the development of the surgical robotics market in the region, the first procedures using the da Vinci system were carried out in Riga in May this year — with the participation of doctors from the hospital in Rzeszów — opening the robotic surgery programme in the Baltic states.
“We are currently in talks on three further robotic system installations in the Baltic states – in both public and private hospitals. This shows that the Group’s consistently built presence in the region is paying off. We are consistently pursuing our strategy of geographic and product diversification of our sales. Over the next two to three financial years, we would like foreign markets to account for around 30% of the Group’s revenue, up from about 21% after the first three quarters of the current financial year,” says Cezary Kozanecki, CEO of Synektik.
“The agreement with the Estonian hospital is another example of how long-term service contracts build our base of recurring revenue – in this case, we can plan for as much as nine years of maintenance care and ten years of consumables supply. Contracts like this give us greater confidence in the predictability of our results than the sale of new equipment alone. The value of our recurring revenue is growing year on year, and our goal is to increase its share of the Group’s total revenue to around 60%,” notes Dariusz Korecki, Vice President of the Management Board and CFO of Synektik.
As at the end of June 2026, the Synektik Group had a total of 142 da Vinci systems under its care in the region, including 100 in Poland and 42 in the Czech Republic and Slovakia.
According to Synektik’s report “The Future of Healthcare Automation in Central and Eastern Europe by 2030”, the region is still 5-10 years behind Western Europe in terms of the penetration of surgical robotics, artificial intelligence and hospital pharmacy automation. This process is expected to be accelerated by hospitals’ growing modernisation needs and new EU regulations on digitalisation and data security in healthcare.
The Baltic region is not the Group’s only direction of expansion – this year Synektik also launched operations in Ukraine, where it plans to install around 20 da Vinci systems over the next two years.
Expansion is not just about da Vinci robots
Geographic expansion is going hand in hand with the broadening of the Group’s product offering and new projects. In July, Synektik, working with Israel’s Insightec, delivered the first Exablate Neuro system in Slovakia, used for the non-invasive treatment of essential tremor and tremor caused by Parkinson’s disease. The equipment went to a centre in Nitra.
In June this year, the Edison system of the US company HistoSonics, used for the non-invasive treatment of liver tumours, received CE certification, allowing it to be sold throughout the European Union. As the exclusive distributor of the Edison system in Poland, the Czech Republic, Slovakia and the Baltic states, the Synektik Group can now begin commercialising the system in these markets.
The Group’s IT segment is also growing rapidly – together with its Czech partner Carebot, Synektik is currently delivering two contracts for Poland’s e-Health Centre (Centrum e-Zdrowia) to implement artificial intelligence models for detecting cancerous lesions in mammography and pathological changes in chest X-rays.
